However, HOXB9 is negatively correlated with PD-L1 expression (Supplementary Figure 2C), so it is speculated that the use of PD-L1 inhibitors in NSCLC with high HOXB9 expression may not benefit significantly. The gene discussed is HOXB9; the disease is non-small cell lung carcinoma.